nab-Paclitaxel/Carboplatin in Vulnerable Populations With Advanced Non-Small Cell Lung Cancer: Pooled Analysis

INTRODUCTION: Despite improvements in the treatment of advanced non-small cell lung cancer (NSCLC), certain patient populations remain underrepresented in clinical trials. Many patients have benefited from platinum doublets, including nab-paclitaxel–based regimens, but there are patients with comorb...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Oncol
Main Authors: Langer, Corey J., Gajra, Ajeet, Gridelli, Cesare, Konduri, Kartik, Morgensztern, Daniel, Spigel, David, Talbot, Denis, Thomas, Michael, Weiss, Jared, Pilot, Richard, Bhore, Rafia, Wolfsteiner, Marianne, Ong, Teng Jin, Socinski, Mark
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2021
Assuntos:
Oncology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7871002/
https://ncbi.nlm.nih.gov/pubmed/33575203
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fonc.2020.485587
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares